Home>Topics>Stocks>Amicus Therapeutics

Amicus Therapeutics FOLD

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Amicus Therapeutics' ( FOLD ) CEO John Crowley on Phase III Fabry Monotherapy Study Results (Transcript)

      Headlines

      Wed, 20 Aug 2014

      By SA Transcripts : Amicus Therapeutics , Inc. (NASDAQ: FOLD ) Phase III Fabry Monotherapy Study Results Conference ..... Good day, ladies and gentlemen, and welcome to the Amicus Phase 3 Fabry monotherapy results conference call. At

    2. Amicus Fabry disease drug candidate successful in Phase 3 trial

      Headlines

      Wed, 20 Aug 2014

      Share of Amicus Therapeutics (NASDAQ: FOLD ) are up 37% premarket on light volume in response to its report of positive results for its Fabry disease drug candidate, migalstat

    3. Amicus's fat accumulation drug effective in second late-stage study

      Headlines

      Wed, 20 Aug 2014

      Aug 20 (Reuters) - Amicus Therapeutics Inc said its experimental drug was as effective as enzyme replacement therapies (ERTs) after 18 months in patients with an inherited disorder that leads to the...

    4. BUZZ- Amicus Therapeutics : On track to report trial data

      Headlines

      Mon, 30 Jun 2014

      ** Says on track to report data from a late-stage trial of its genetic disorder drug in the third quarter of this year

    5. Amicus shares fall after Fabry drug fails late-stage study

      Headlines

      Thu, 20 Dec 2012

      (Reuters) - Amicus Therapeutics Inc lost nearly half of its market value after the company said its experimental drug to treat a rare, inherited disorder failed to meet the main goal of a late-stage...

    6. Amicus's shares tank after Fabry disease drug fails trial

      Headlines

      Wed, 19 Dec 2012

      (Reuters) - Amicus Therapeutics said its experimental drug to treat a rare, inherited disorder failed to meet the main goal of a late-stage study, sending its shares down 50 percent in extended...

    7. Dropping Coverage of Amicus

      Commentary

      Tue, 29 Jun 2010

      We are no longer providing equity research on Amicus Therapeutics FOLD . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.

    8. New Morningstar Analyst Report - Amicus Therapeutics , Inc.

      Stock Reports

      Wed, 16 Jun 2010

      Shire's collaboration with Amicus also bodes poorly for Amigal's ..... only worsen the problem. Amicus is more dependent than ever ..... future drug development. Amicus aims to use its innovative ..... partner to market them abroad. Amicus Therapeutics aims to stand on the shoulders

    9. New Morningstar Analyst Report - Shire PLC

      Stock Reports

      Tue, 4 May 2010

      in 2008 of Dynepo ( from Transkaryotic Therapies ) after lackluster sales , and terminated a rare disease partnership with Amicus FOLD in 2009 following weak clinical data . While Adderall XR's generic competition is a drag on the top line , Vyvanse is experiencing

    10. New Morningstar Analyst Report - Shire PLC

      Stock Reports

      Fri, 5 Feb 2010

      in 2008 of Dynepo (from Transkaryotic Therapies) after lackluster sales, and terminated a rare disease partnership with Amicus FOLD in 2009 following weak clinical data.While Adderall XR's generic competition is a drag on the top line, Vyvanse is experiencing

    « Prev12Next »
    Content Partners